You have 9 free searches left this month | for more free features.
Clincosm LogoSign in Get a demo

Kymriah

Showing 1 - 18 of 18
STUDY
CONDITIONS
INTERVENTIONS
LOCATIONS
LAST UPDATED

Lymphoma, Large B-Cell, Diffuse Trial (Cyclophosphamide, TLI, Fludarabine)

Not yet recruiting
  • Lymphoma, Large B-Cell, Diffuse
  • (no location specified)
Aug 18, 2023

Refractory Diffuse Large B-cell Lymphoma, Refractory DLBCL, Not Otherwise Specified, Recurrent DLBCL Trial in Duarte, Saint

Recruiting
  • Refractory Diffuse Large B-cell Lymphoma
  • +4 more
  • Duarte, California
  • +2 more
Aug 9, 2022

DLBCL, Diffuse Large B Cell Lymphoma, High-grade B-cell Lymphoma Trial in Minneapolis (E7777)

Recruiting
  • DLBCL
  • +3 more
  • Minneapolis, Minnesota
    University of Minnesota, Masonic Cancer Center
Jul 1, 2022

CAR T Cells Real World Evidence Study Based on French Hospital

Completed
  • Diffuse Large B-Cell Lymphoma (DLBCL)
  • Acute Lymphoblastic Leukemia (ALL)
  • KYMRIAH
  • YESCARTA
  • East Hanover, New Jersey
    Novartis Investigative Site
Jun 29, 2022

MT2017-45: CAR-T Cell Therapy for Heme Malignancies

Recruiting
  • Acute Lymphoblastic Leukemia
  • Large B-cell Lymphoma
  • KYMRIAH
  • +8 more
  • Minneapolis, Minnesota
    Masonic Cancer Center at University of Minnesota
Nov 2, 2022

Primary CNS Lymphoma, Refractory Primary CNS Lymphoma, Relapsed Primary CNS Lymphoma Trial in Boston (Tisagenlecleucel)

Recruiting
  • Primary CNS Lymphoma
  • +2 more
  • Tisagenlecleucel
  • Boston, Massachusetts
    Massachusetts General Hospital
Jan 18, 2021

DLBCL, Grade 3b Follicular Lymphoma, Primary Mediastinal (Thymic) Large B-Cell Lymphoma Trial (biological, procedure, drug,

Not yet recruiting
  • Diffuse Large B-Cell Lymphoma
  • +6 more
  • Axicabtagene Ciloleucel
  • +10 more
  • (no location specified)
Jan 13, 2023

Acute Lymphoblastic Leukemia Trial (Tisagenlecleucel, Blinatumomab, Inotuzumab)

Withdrawn
  • Acute Lymphoblastic Leukemia
  • Tisagenlecleucel
  • +2 more
  • (no location specified)
Jul 7, 2020

Pediatric and Young Adult B-Cell Malignancies After Commercially

Not yet recruiting
  • Lymphoid Leukemia
  • Questionnaire for patients receiving therapy
  • Palo Alto, California
    Stanford University
May 9, 2023

Biological Samples From Patients Treated With CAR-T Cells for

Recruiting
  • Lymphoma and Acute Lymphoblastic Leukemia
  • additional biological samples during CAR-T CELL treatment
  • Montpellier, France
    Département d'hématologie clinique
Dec 21, 2021

Relapse Leukemia, Refractory Leukemia Trial in Shenzhen (Allogeneic CD19 CAR-T cells)

Recruiting
  • Relapse Leukemia
  • Refractory Leukemia
  • Allogeneic CD19 CAR-T cells
  • Shenzhen, Guangdong, China
    Li Yu
Dec 7, 2021

People Living With HIV Treated With CD19-directed CAR T Cell

Active, not recruiting
  • Leukemia
  • +9 more
    • Philadelphia, Pennsylvania
      Pennsylvania Hospital
    Mar 29, 2023

    Patients Undergoing CAR-T Cell Therapy (CAR_21_01)

    Recruiting
    • CAR-T Therapy Complications
      • Bologna, Italy
        IRCC, University Hospital of Bologna
      Mar 18, 2022

      Hematologic Malignancy Trial in Bologna

      Recruiting
      • Hematologic Malignancy
        • Bologna, Italy
          Programma Dipartimentale Terapie Cellulari Avanzate
        Apr 17, 2023

        Non-Hodgkin Lymphoma Trial in Worldwide (Tisagenlecleucel after optional bridging and lymphodepleting chemo, Platinum-based

        Active, not recruiting
        • Non-Hodgkin Lymphoma
        • Tisagenlecleucel after optional bridging and lymphodepleting chemotherapy
        • Platinum-based immunochemotherapy followed in responding patients with high dose chemotherapy and autologous hematopoietic stem cell transplant (HSCT)
        • La Jolla, California
        • +66 more
        Jan 6, 2023

        Diffuse Large B Cell Lymphoma, Primary Mediastinal Large B Cell Lymphoma, Large B-cell Lymphoma Trial in Kaohsiung, Taipei

        Recruiting
        • Diffuse Large B Cell Lymphoma
        • +4 more
        • CD19-targeted chimeric antigen receptor T-cell
        • Kaohsiung, Taiwan
        • +2 more
        Oct 25, 2022

        Quality Of Life and Drug Use in Patients With CAR-T Cells

        Recruiting
        • Patients With Diffuse Large B-cell Lymphoma Treated With CART-cells
        • Semi-structured interviews and self-administered questionnaires
        • Pierre-Bénite, France
          Hospices Civils de Lyon -Groupement Hospitalier Sud Service phar
        Feb 1, 2022

        B Acute Lymphoblastic Leukemia, Acute Lymphoblastic Leukemia, in Relapse Trial (Decreasing starting times for beginning

        Not yet recruiting
        • B Acute Lymphoblastic Leukemia
        • Acute Lymphoblastic Leukemia, in Relapse
        • Decreasing starting times for beginning nivolumab (Time to Event Continual Reassessment Method (TITE-CRM) )
        • Nivolumab starting at day -1
        • (no location specified)
        Apr 4, 2022